Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement

• Charlotte Rigaud,
• Samuel Abbou,
• Stephane Ducassou,
• Mathieu Simonin,
• Lou Le Mouel,
• Victor Pereira,
• Stephanie Gourdon,
• Anne Lambilliotte,
• Birgit Geoerger,
• Veronique Minard-Colin,
• Laurence Brugieres

Affiliations

Charlotte Rigaud

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif

Samuel Abbou

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif

Stephane Ducassou

Department of Pediatric Oncology and Hematology, Bordeaux University hospital, Bordeaux

Mathieu Simonin

Department of Pediatric Oncology and Hematology, Armand Trousseau Hospital- APHP, Paris

Lou Le Mouel

Department of Pediatric Hematology, Robert Debré Hospital- APHP, Paris

Victor Pereira

Department of Pediatric Oncology and Hematology, Besançon University Hospital, Besançon

Stephanie Gourdon

Department of Pediatric Oncology and Hematology, Saint-Denis de la Réunion University Hospital

Anne Lambilliotte

Department of Pediatric Hematology, Lille University Hospital, Lille

Birgit Geoerger

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif

Veronique Minard-Colin

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif

Laurence Brugieres

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif